Narcolepsy - Pipeline Review, H1 2016

Date: April 27, 2016
Pages: 72
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NF8C48075DAEN
Leaflet:

Download PDF Leaflet

Narcolepsy - Pipeline Review, H1 2016

SUMMARY

Global Markets Direct’s, ‘Narcolepsy - Pipeline Review, H1 2016’, provides an overview of the Narcolepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Narcolepsy
  • The report reviews pipeline therapeutics for Narcolepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Narcolepsy therapeutics and enlists all their major and minor projects
  • The report assesses Narcolepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Narcolepsy
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Narcolepsy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Narcolepsy Overview
Therapeutics Development
Pipeline Products for Narcolepsy - Overview
Pipeline Products for Narcolepsy - Comparative Analysis
Narcolepsy - Therapeutics under Development by Companies
Narcolepsy - Therapeutics under Investigation by Universities/Institutes
Narcolepsy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Narcolepsy - Products under Development by Companies
Narcolepsy - Products under Investigation by Universities/Institutes
Narcolepsy - Companies Involved in Therapeutics Development
Bioprojet SCR
Evotec AG
Flamel Technologies S.A.
H.A.C. Pharma
Jazz Pharmaceuticals Plc
NLS Pharma Group
Sanofi
SK Biopharmaceuticals Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
Theranexus SAS
Narcolepsy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(modafinil + THN-02) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JZP-386 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NLS-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentylenetetrazol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pitolisant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-110068 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SKL-N05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Orexin Receptor for EDS and Narcolepsy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sodium oxybate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sodium oxybate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TS-091 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Narcolepsy - Recent Pipeline Updates
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Featured News & Press Releases
Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate
Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep
Nov 20, 2015: Narcolepsy treatment recommended for approval
Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies
Jun 04, 2015: Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem(sodium oxybate) at SLEEP 2015
May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate
Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy
Jul 21, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Narcolepsy, H1 2016
Number of Products under Development for Narcolepsy - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Narcolepsy - Pipeline by Bioprojet SCR, H1 2016
Narcolepsy - Pipeline by Evotec AG, H1 2016
Narcolepsy - Pipeline by Flamel Technologies S.A., H1 2016
Narcolepsy - Pipeline by H.A.C. Pharma, H1 2016
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2016
Narcolepsy - Pipeline by NLS Pharma Group, H1 2016
Narcolepsy - Pipeline by Sanofi, H1 2016
Narcolepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016
Narcolepsy - Pipeline by Theranexus SAS, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Narcolepsy Therapeutics - Recent Pipeline Updates, H1 2016
Narcolepsy - Dormant Projects, H1 2016
Narcolepsy - Discontinued Products, H1 2016

LIST OF FIGURES

Number of Products under Development for Narcolepsy, H1 2016
Number of Products under Development for Narcolepsy - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

COMPANIES MENTIONED

Bioprojet SCR
Evotec AG
Flamel Technologies S.A.
H.A.C. Pharma
Jazz Pharmaceuticals Plc
NLS Pharma Group
Sanofi
SK Biopharmaceuticals Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
Theranexus SAS
Skip to top


Ask Your Question

Narcolepsy - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: